CANCER CELL LINES

ONCOLOGY

To support drug discovery projects in oncology, we perform high-content analysis either in cellular models of human tumors in 2D or 3D, or directly in tumor tissues and blood samples. Combining a panel of validated assays for immediate performance and more than 10-year experience in assay development, we assist pharmaceutical companies and academic researchers in the discovery of new cancer drug targets, the identification of new anticancer compounds, and the quantitative analysis of novel cancer biomarkers.

CANCER CELL LINES

Fluofarma maintains a panel of human cancer cell lines to establish in vitro tumor models in 2D or 3D. Isolated from tissue-specific tumors and grown in vitro, cancer cell lines are particularly suited for anti-cancer drug screening.

TISSUE-SPECIFIC HUMAN CANCER CELL LINES

(Please contact us if you want us to test your compounds in a specific model: several cell lines are available for each tumor type, and our panel is regularly augmented with new cell lines)

LYMPHATIC SYSTEM Burkitt's lymphoma
Diffuse large B cell lymphoma
Follicular lymphoma
Hodgkin's lymphoma
Non-Hodgkin's B cell lymphoma
IMMUNE SYSTEM Acute T cell leukemia
Acute lymphoblastic leukemia
Monocyte leukemia
Promyelocytic leukemia
MAMMARY SYSTEM Breast carcinoma
DIGESTIVE SYSTEM
CARCINOMAS		 Colorectal carcinoma
Hepatoma
Pancreas carcinoma
UROGENITAL SYSTEM  Bladder carcinoma
Cervical adenocarcinoma
Prostate carcinoma
BRAIN & ENDOCRINE 
SYSTEM TUMORS		 Glioblastoma
Neuroblastoma
Pheochromocytoma
Pituitary adenoma
SKIN AND SOFT 
TISSUES CANCERS		 Fibrosarcoma
Melanoma
LUNG CANCER Alveolar basal epithelial lung Adenocarcinoma

A UNIQUE PROPRIETARY BIOSENSOR TECHNOLOGY

Fluofarma has applied its proprietary biosensor technology (DAPS) to a number of cell lines within this panel, thus allowing the reagent-less quantification of caspase, gamma-secretase and calpain activity by high-throughput flow cytometry.

>>> Learn more about our drug discovery services in oncology, or more generally, about our preclinical services.

Phase contrast image of bladder cell line

Phase contrast image of bladder cell line

HaCaT (human keratinocytes) cell migration into the wound in non-treated (A) and 48h FBS-treated (B) conditions.

HaCaT (human keratinocytes) cell migration into the wound in non-treated (A) and 48h FBS-treated (B) conditions.

Principle of Fluofarma's caspase-3 biosensor. When caspase-3 is inactive, the biosensor remains mitochondrially located. Thus, the fluorescence signal is detected even after permeabilization. When caspase-3 is active, the biosensor is cleaved and GFP fragment is released in the cytosol and then drained off from the cell after permeabilization, cells thereby becoming non-fluorescent.

Principle of Fluofarma's caspase-3 biosensor. When caspase-3 is inactive, the biosensor remains mitochondrially located. Thus, the fluorescence signal is detected even after permeabilization. When caspase-3 is active, the biosensor is cleaved and GFP fragment is released in the cytosol and then drained off from the cell after permeabilization, cells thereby becoming non-fluorescent.